Skip to main content

Clinical Trials Using Prednisone

Review the clinical trials studying prednisone on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 109

Epcoritamab in Combination with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-miniCVP) for Older, Unfit and Frail Patients or Anthracycline-Ineligible Patients with Diffuse Large B-Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Consolidation Therapy (R-EPOCH) for the Treatment of Patients with Posttransplant Lymphoproliferative Disorder
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Ruxolitinib in Combination with Recombinant Human Chorionic Gonadotropin and Corticosteroids for the Treatment of Lower Gastrointestinal Acute Graft Versus Host Disease in Patients Who Have Undergone Hematopoietic Cell Transplant
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Mosunetuzumab with Chemotherapy for the Treatment of Patients with Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Tafasitamab, Retifanlimab, and Rituximab in Combination with Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Polatuzumab Vedotin and Rituximab With or Without Chemotherapy for the Treatment of Post-Transplant Lymphoproliferative Disorder
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Hyper-CVAD in Combination with Venetoclax for the Treatment of Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Loncastuximab and Roflumilast in Combination with R-CHOP (Lo-RR-CHOP) for the Treatment of High-Risk Diffuse Large B-cell Lymphoma
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Ruxolitinib in Combination with CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: See ClinicalTrials.gov
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Status: Enrolling by Invitation
Location: 2 locations
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 149 locations
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants with Metastatic Castration Resistant Prostate Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Olaparib, Cabazitaxel, Carboplatin, and Prednisone in Treating Patients with Metastatic Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 82 locations